Ensysce Biosciences annual stock-based compensation
2020
2021
2022
2023
2024
2025
Ensysce Biosciences Stock-Based Compensation Growth & History (ENSC)
Ensysce Biosciences's stock-based compensation was $177,086 for fiscal 2025.
View full Ensysce Biosciences company overviewEnsysce Biosciences annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $177,086 | $66,363 | +59.94% |
| 2024 | 2024-12-31 | $110,723 | −$768,437 | −87.41% |
| 2023 | 2023-12-31 | $879,160 | −$192,683 | −17.98% |
| 2022 | 2022-12-31 | $1.1M | $950,079 | +780.26% |
| 2021 | 2021-12-31 | $121,764 | −$56,915 | −31.85% |
| 2020 | 2020-12-31 | $178,679 | — | — |
Ensysce Biosciences quarterly stock-based compensation
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1,870 | −$184,893 | −99.00% |
| Q1 2026 | 2026-03-31 | $8,743 | −$7,508 | −46.20% |
| Q4 2025 | 2025-12-31 | $24,339 | −$5,810 | −19.27% |
| Q3 2025 | 2025-09-30 | −$50,267 | −$71,085 | — |
| Q2 2025 | 2025-06-30 | $186,763 | $160,214 | +603.47% |
| Q1 2025 | 2025-03-31 | $16,251 | −$16,956 | −51.06% |
| Q4 2024 | 2024-12-31 | $30,149 | −$598,787 | −95.21% |
| Q3 2024 | 2024-09-30 | $20,818 | −$34,856 | −62.61% |
| Q2 2024 | 2024-06-30 | $26,549 | −$50,868 | −65.71% |
| Q1 2024 | 2024-03-31 | $33,207 | −$83,926 | −71.65% |
| Q4 2023 | 2023-12-31 | $628,936 | $412,253 | +190.26% |
| Q3 2023 | 2023-09-30 | $55,674 | −$101,473 | −64.57% |
| Q2 2023 | 2023-06-30 | $77,417 | −$218,162 | −73.81% |
| Q1 2023 | 2023-03-31 | $117,133 | −$285,301 | −70.89% |
| Q4 2022 | 2022-12-31 | $216,683 | $199,945 | +1194.56% |
| Q3 2022 | 2022-09-30 | $157,147 | $132,314 | +532.82% |
| Q2 2022 | 2022-06-30 | $295,579 | $259,206 | +712.63% |
| Q1 2022 | 2022-03-31 | $402,434 | $358,614 | +818.38% |
| Q4 2021 | 2021-12-31 | $16,738 | — | — |
| Q3 2021 | 2021-09-30 | $24,833 | −$26,677 | −51.79% |
| Q2 2021 | 2021-06-30 | $36,373 | — | — |
| Q1 2021 | 2021-03-31 | $43,820 | — | — |
| Q3 2020 | 2020-09-30 | $51,510 | — | — |
Ensysce Biosciences stock-based compensation trends
Over the last five fiscal years, Ensysce Biosciences's stock-based compensation decreased from $178,679 to $177,086, a change of −$1,593. The latest reported quarter, Q2 2026, shows $1,870.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ensysce Biosciences source filings ↗